<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00876304</url>
  </required_header>
  <id_info>
    <org_study_id>B0911004</org_study_id>
    <nct_id>NCT00876304</nct_id>
  </id_info>
  <brief_title>Multiple Dose Safety Study of PF-04802540 in Subjects With Schizophrenia</brief_title>
  <official_title>Phase 1, Investigator And Subject-Blind, Placebo-Controlled, Randomized, Sequential Group, Multiple Ascending Dose Study To Assess The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of PF-04802540 In Patients With Schizophrenia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Taisho Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Taisho Pharmaceutical Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics of
      multiple ascending doses of PF-04802540 administered orally to subjects with schizophrenia.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2009</start_date>
  <completion_date type="Actual">September 2009</completion_date>
  <primary_completion_date type="Actual">September 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety assessments: vital signs, ECG, physical examination, laboratory tests, Columbia - Suicide Severity Rating Scale</measure>
    <time_frame>22 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>22 Days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma concentrations of PF 04802540 and its metabolite, PF 04831035</measure>
    <time_frame>12 Days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Positive and Negative Syndrome Scale</measure>
    <time_frame>16 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Global Impression of Severity and Improvement</measure>
    <time_frame>16 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Extrapyramidal Symptom Rating Scale - Abbreviated</measure>
    <time_frame>16 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">39</enrollment>
  <condition>Schizophrenia</condition>
  <arm_group>
    <arm_group_label>PF-04802540</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-04802540</intervention_name>
    <description>Multiple ascending doses for 10 days; planned doses include capsules totaling 5 mg and 20 mg every 12 hours, with additional doses determined based on accumulating data</description>
    <arm_group_label>PF-04802540</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo capsules every 12 hours for 10 days</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males or females of non-childbearing capacity aged 18 to 55 years inclusive

          -  DSM-IV diagnosis of schizophrenia, stable symptoms for at least 3 months

          -  Body mass index in the range of 18 to 40 kg/m2 and body weight&gt;45 kg.

        Exclusion Criteria:

          -  Evidence or history of a primary DSM IV axis I diagnosis other than schizophrenia.

          -  Evidence or history of clinically significant hematological, renal, endocrine,
             pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or
             allergic disease

          -  Any condition possibly affecting drug absorption (eg, gastrectomy).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Glendale</city>
        <state>California</state>
        <zip>91206</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B0911004&amp;StudyName=Multiple%20Dose%20Safety%20Study%20of%20PF-04802540%20in%20Subjects%20With%20Schizophrenia</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>October 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 3, 2009</study_first_submitted>
  <study_first_submitted_qc>April 3, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 6, 2009</study_first_posted>
  <last_update_submitted>March 17, 2010</last_update_submitted>
  <last_update_submitted_qc>March 17, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 19, 2010</last_update_posted>
  <responsible_party>
    <organization>Taisho Pharmaceutical Co., Ltd.</organization>
  </responsible_party>
  <keyword>PF-04802540 multiple dose safety study</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schizophrenia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

